论文部分内容阅读
目的：评价优妥缓释剂在５６例ＲＡ患者的安全性和有效性。方法：开放试验，受试者ｐｏ优妥９０ｍｇ，疗程３周，对比治疗前和疗程结束时患者关节疼痛、压痛和肿胀、晨僵、握力、血沉和ＣＲＰ等指标变化，评价其疗效。结果：治疗后所有观察指标均获显著改善（Ｐ＜０．０１或０．０５），显著进步和进步率达７６．８％。副反应发生率１４．３％，无撤药者。结论：优妥为一抗炎止痛作用强、疗效快及副作用小的新药物。
OBJECTIVE: To evaluate the safety and efficacy of YUDU sustained-release agent in 56 patients with RA. Methods: In the open trial, the trial of pooleutuo 90mg for 3 weeks was performed to evaluate the curative effect of arthritis pain, tenderness and swelling, morning stiffness, grip strength, erythrocyte sedimentation rate and CRP before and at the end of treatment. Results: After treatment, all the observation indicators were significantly improved (P <0.01 or 0.05), significant progress and progress rate of 76.8%. The incidence of side effects 14.3%, no withdrawal of those. Conclusion: Euthyroid is an anti-inflammatory and analgesic effect of strong, rapid and less side effects of new drugs.